1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-6-[4-bromophenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one | 280119-65-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-6-[4-bromophenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one
• 英文别名: Ethyl 6-(4-bromophenyl)-1-(4-methoxyphenyl)-7-oxopyrazolo[4,3-d]pyrimidine-3-carboxylate
• CAS: 280119-65-5
• 化学式: C₂₁H₁₇BrN₄O₄
• 分子量: 469.294
• InChiKey: OWIVJESHMQMVTI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  86
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-6-[4-bromophenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one 在 ammonium hydroxide 、 sodium tetrahydroborate 、 四(三苯基膦)钯 、 三溴化磷 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 乙腈 、 苯 为溶剂， 生成 6-[4-(2-{[(3R)-3-hydroxypyrrolidin-1-yl]methyl}phenyl)phenyl]-1-(4-methoxyphenyl)-7-oxo-1H,6H,7H-pyrazolo[4,3-d]pyrimidine-3-carboxamide
  参考文献：
  名称：

  Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa

  摘要：

  Previously, potent factor Xa inhibitors were described based on a pyrazole core. Modifications of the pyrazole core have provided additional novel, highly potent factor Xa inhibitors. This manuscript will describe the synthesis and biological activity of factor Xa inhibitors containing the 1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one and related bicyclic cores. Many of these compounds are potent, selective, and orally bioavailable inhibitors of coagulation factor Xa. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.04.044
• 作为产物：
  描述：

  (1-[4-Methoxyphenyl]-3-(ethoxycarbonyl)-4-azido)pyrazole-5-carboxylic acid 在 草酰氯 、 tin(ll) chloride 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 2.0h， 生成 1-[4-methoxyphenyl]-3-(ethoxycarbonyl)-6-[4-bromophenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one
  参考文献：
  名称：

  Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa

  摘要：

  Previously, potent factor Xa inhibitors were described based on a pyrazole core. Modifications of the pyrazole core have provided additional novel, highly potent factor Xa inhibitors. This manuscript will describe the synthesis and biological activity of factor Xa inhibitors containing the 1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one and related bicyclic cores. Many of these compounds are potent, selective, and orally bioavailable inhibitors of coagulation factor Xa. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.04.044

文献信息

• Nitrogen containing heterobicycles as factor Xa inhibitors
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：US06413980B1

  公开（公告）日：2002-07-02

  The present application describes nitrogen containing heterobicyclics and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

  本申请描述了含氮杂双环化合物及其衍生物，或其药用盐形式，这些化合物可作为因子Xa的抑制剂。
• NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：EP1140941B1

  公开（公告）日：2004-10-20
• US6413980B1
  申请人：——

  公开号：US6413980B1

  公开（公告）日：2002-07-02
• US6858616B2
  申请人：——

  公开号：US6858616B2

  公开（公告）日：2005-02-22
• Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa
  作者：John M. Fevig、Joseph Cacciola、Joseph Buriak、Karen A. Rossi、Robert M. Knabb、Joseph M. Luettgen、Pancras C. Wong、Stephen A. Bai、Ruth R. Wexler、Patrick Y.S. Lam

  DOI：10.1016/j.bmcl.2006.04.044

  日期：2006.7

  Previously, potent factor Xa inhibitors were described based on a pyrazole core. Modifications of the pyrazole core have provided additional novel, highly potent factor Xa inhibitors. This manuscript will describe the synthesis and biological activity of factor Xa inhibitors containing the 1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one and related bicyclic cores. Many of these compounds are potent, selective, and orally bioavailable inhibitors of coagulation factor Xa. (c) 2006 Elsevier Ltd. All rights reserved.